The Lynx Group

Rachel Laing, PhD; Olivier Lesueur


Authored Items

Immuno-Oncology Brings New Opportunities for Developers of Targeted Cytotoxics

September 2015, Vol. 2, No. 5 - Editorial

Among the highlights of this year’s American Society of Clinical Oncology Annual Meeting were outstanding data from the combination of Bristol- Myers Squibb’s nivolumab and ipilimumab, which produced a longer progression-free survival than ipilimumab alone in non–BRAF-mutated melanoma. Companies are furiously mixing and matching combinations of their immuno-oncology therapies to [ Read More ]

Sign me up!